Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura

Transfusion

Volumn 52, Issue 12, 2012, Pages 2517-2523

  Bhagirath, Vinai C ^a   Kelton, John G ^a   Moore, Jane ^a   Arnold, Donald M ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEFIBROTIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE; VINDESINE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTHRALGIA; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE CHEMOTHERAPY; MALAISE; NEUROLOGIC DISEASE; PLASMAPHERESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; SERUM SICKNESS; SINGLE DRUG DOSE; SPLENECTOMY; STEROID THERAPY; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84871025410     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03635.x     Document Type: Article

References (33)

1. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA,. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-7.
2. Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN,. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-11.
3. Elliott MA, Heit JA, Pruthi RK, Gastineau DA, Winters JL, Hook CC,. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol 2009; 83: 365-72.
4. Chemnitz JM, Uener J, Hallek M, Scheid C,. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol 2010; 10: 1023-33.
5. de la Rubia J, Moscardo F, Gómez MJ, Guardia R, Rodríguez P, Sebrango A, Zamora C, Debén G, Goterris R, López R, Peña F, Pujol M, Vidaller A, Del Río-Garma J, Sanz MA,; Grupo Español de Aféresis. Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study. Transfus Apher Sci 2010; 43: 299-303.
6. Moore JC, Hayward CP, Warkentin TE, Kelton JG,. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001; 98: 1842-6.
7. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B,. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
8. Galbusera M, Bresin E, Noris M, Gastoldi S, Belotti D, Capoferri C, Daina E, Perseghin P, Scheiflinger F, Fakhouri F, Grünfeld JP, Pogliani E, Remuzzi G,. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood 2005; 106: 925-8.
9. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, Rieger M, Scheiflinger F, Poullin P, Deroure B, Delarue R, Lesavre P, Vanhille P, Hermine O, Remuzzi G, Grünfeld JP,. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005; 106: 1932-7.
10. Benetatos L, Vassou A, Bourantas KL,. Effectiveness of rituximab as prophylaxis in thrombotic thrombocytopenic purpura. Clin Lab Haematol 2006; 28: 288-9.
11. Schleinitz N, Ebbo M, Mazodier K, Poullin P, Bernit E, Veit V, Veyradier A, Fakhouri F, Kaplanski G, Harle JR,. Rituximab as preventive therapy of a clinical relapse in TTP with ADAMTS13 inhibitor. Am J Hematol 2007; 82: 417-8.
12. Bresin E, Gastoldi S, Daina E, Belotti D, Pogliani E, Perseghin P, Scalzulli PR, Paolini R, Marcenò R, Remuzzi G, Galbusera M,. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost 2009; 101: 233-8.
13. Jayabose S, Dunbar J, Nowicki TS, Tugal O, Ozkaynak MF, Sandoval C,. Rituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child. Pediatr Hematol Oncol 2010; 28: 167-72.
14. Ojeda-Uribe M, Federici L, Wolf M, Coppo P, Veyradier A,. Successful long-term rituximab maintenance for a relapsing patient with idiopathic thrombotic thrombocytopenic purpura. Transfusion 2010; 50: 733-5.
15. Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Tilly H, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42-51.
16. Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreño L, Armstrong G, Collinson N, Shaw TM,; MIRROR Trial Investigators. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford) 2010; 49: 1683-93.
17. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG,. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146: 25-33.
18. Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, Bocchia M, Medeot M, De Luca S, Ferrara F, Isola M, Baccarani M, Fanin R,. Low dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol 2010; 85: 329-34.
19. McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA,. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8: 1201-8.
20. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, Mackie I, Machin SJ,. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007; 136: 451-61.
21. Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ,. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118: 1746-53.
22. Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, Schwarzinger M, Galicier L, Vanhille P, Vernant JP, Bordessoule D, Guidet B, Azoulay E, Mariotte E, Rondeau E, Mira JP, Wynckel A, Clabault K, Choukroun G, Presne C, Pourrat J, Hamidou M, Coppo P,; French Thromb. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 2012; 40: 104-11.
23. Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T,. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011; 76: 1310-5.
24. Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, Amadori S,. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110: 2924-30.
25. Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V, Söhngen D,. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 2002; 71: 105-8.
26. Ahmad A, Aggarwal A, Sharma D, Dave HP, Kinsella V, Rick ME, Schechter GP,. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 2004; 77: 171-6.
27. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB,. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004; 125: 232-9.
28. Bussel JB,. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol 2000; 37: 261-6.
29. Bohm M, Betz C, Miesbach W, Krause M, von Auer C, Geiger H, Scharrer I,. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol 2005; 129: 644-52.
30. Hellerstedt B, Ahmed A,. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol 2003; 14: 1792.
31. Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME,. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 2007; 109: 2182-9.
32. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL,. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-40.
33. De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C, Tavoni A, Pietrogrande M, Ferri C, Mascia M, Masolini P, Zabotti A, Maset M, Roccatello D, Zignego A, Pioltelli P, Gabrielli A, Filippini D, Perrella O, Migliaresi S, Galli M, Bombardieri S, Monti G,. A randomized, controlled, trial of rituximab for treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64: 843-53.